Prf Technologies Ltd. · NASDAQ:PRFX
Prf Technologies — PainReform — Investor Presentation (April 2022)
19 slides from Prf Technologies's investor presentation, April 2022
Slide 1: Investor Presentation
Investor Presentation April 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about our expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”,
Slide 3: Highly experienced management Team
Highly experienced management Team Ehud Geller, PhD, MBA. Executive Chairman Former President & CEO of Interpharm Laboratories and EVP of Teva Group Former head of the Israeli Pharmaceutical Manufacturers Association and board member of the Tel Aviv Stock Exchange National Industry award for c
Slide 4: PRF-110 Executive Summary
PRF-110 Executive Summary Post-operative pain treatment is a growing market (~$12B) with a need for better therapeutics1 o Local anesthetics provide pain relief for up to 6 hours and require augmentation with non-steroidal anti-inflammatory drugs (NSAIDs) o NSAIDs or opioids for moderate to severe
Slide 5: Post-Operative Pain Management Market Overview
Post-Operative Pain Management Market Overview The 2017 North America post-operative pain treatment market was estimated at ~$12B and is expected to reach ~$16B and $45B world-wide by the end of 20261 4 Significant unmet need for long-acting local anesthetic agents in order to spare opioids use,
Slide 6: Current Approaches in Post-Operative Analgesia Are Lacking
Current Approaches in Post-Operative Analgesia Are Lacking Short-Acting Opioids Long-Acting Opioids Repeated dosing required Poor efficacy in acute pain control Inconsistent pain control between doses Not intended for the treatment of post-operative pain Dependence risk increases with trea
Slide 7: Prescription Opioids
Prescription Opioids Prescription opioids can be used to treat moderate-to-severe pain and are often prescribed following surgery or injury In recent years, there has been a dramatic increase in the acceptance and use of prescription Opioids Opioid's dependency can start within 3 days of initi
Slide 8: Problem: State of Opioid Crisis in America
Problem: State of Opioid Crisis in America 99% of surgical patients receive opioids to manage post-surgical pain1 and released with opiate prescription Approximately 11.4 million people misused opioids in 2016 and 2019. 886K used heroin. 562K misused both pain relievers and heroin 6% to 10% of
Slide 9: PainReform Solution: PRF-110 Post Operative Pain Management
PainReform Solution: PRF-110 Post Operative Pain Management PRF-110 can reduce the consumption of opioids to manage post-surgical pain Studies have shown 48 hours of pain reduction in healthy volunteers and about 72 hours in a clinical setting PainReform has developed a platform formulation fo
Slide 10: PRF-110 Manufacturing
PRF-110 Manufacturing Engaged Pharmaceutics International, Inc. (PII): US based contract manufacturing organization (CMO) Well experienced in sterile manufacturing PII is a premier, solutions-oriented, science driven CMO with over 25 years of proven success in providing high-quality dosage f
Slide 11: PRF-110: Timeline to NDA
PRF-110: Timeline to NDA Historical Future FDA determined Positive Phase 2, the CMC data proof-of-concept adequate to study in hernia Successful PRF- Study readouts ~9 proceed to Phase repair: pain control 110 production months after dosing I study up to 72 hours in the U.S. first patient Initiate d
Slide 12: Product differentiation PRF-110 vs. Competition
Product differentiation PRF-110 vs. Competition Pacira1 – Exparel™ Heron2 - Zynrelef PRF-110 PRF-110 Advantages Watery, complex liposomal Biochronomer technology: Non-dilutable (Limited Waterless, viscous, oil- Formulation Uniformity, viscosity, & retention suspension market) based solution (GRAS) P
Slide 13: PRF-110 Safety
PRF-110 Safety PainReform carried out extensive FDA requested wound healing and related animal studies that showed: PRF-110 allows for normal wound healing of surgical incisions equal to both Naropin® and saline without any untoward histological or radiologic (microCT) effects observed in soft o
Slide 14: PRF-110 Phase 2 Results in Hernia
PRF-110 Phase 2 Results in Hernia PRF-110 Pain Reduction Up to 72-Hours After a Single Application 8 Efficacy PRF-110 provided post- PBO 7 Historical operative pain control for up to placebo data 72 hours after a single Mean Pain Score 6 PRF-110 application Scale 1-10 5 Safety 4 PRF-110 was
Slide 15: PRF-110: Phase III Clinical Trial Protocol
PRF-110: Phase III Clinical Trial Protocol Two, double blind, placebo control 72-hour treatment period, studies planned (bunionectomy and hernia surgery). For each study: Three cohorts (n= ~400): PRF-110; Naropin® (ropivacaine); placebo; in a 2:2:1 ratio Primary endpoint (Efficacy) • Compare the
Slide 16: PRF-110: Potential Best-In-Class
PRF-110: Potential Best-In-Class Efficacy Safety Cross study comparison of Phase II Met FDA required extensive pre-clinical data, 72 hours pain AUC studies to demonstrate no wound healing issues Administration COGS Low cost of good sold allows a highly PRF-110 viscosity and uniformity are highly str
Slide 17: Summary
Summary 1 2 3 4 5 Innovative Opioid Epidemic Seasoned Robust US and Core platform Formulation / Presents Management International can be utilized Delivery System Significant Team with IP Portfolio for wide-range Commercial Decades of of APIs to Opportunity Experience generate sustainable pipeline La
Slide 18: Key Statistics
Key Statistics NASDAQ: PRFX Current Price (4/11/22): $1.27 Shares Outstanding (4/11/22): 10.5 M Market Cap: $13.3 M Fiscal Year End: December 31 Inside Beneficial Ownership: 34.3% 18 PainReform Ltd.| www.painreform.com Post Operative Pain Management
Slide 19: Thank You
Thank You